The Role of ctDNA as a Biomarker in Colorectal Cancer
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, discuss the role of circulating tumor DNA (ctDNA) as a biomarker in colorectal cancer and provide clinical insights on screening modalities.
Video Player is loading.
Now Viewing
EP: 1.The Role of ctDNA as a Biomarker in Colorectal Cancer
EP: 2.Key Findings from the INTERCEPT Study
EP: 3.Frequency of ctDNA Testing and Future Directions in Detecting MRD
EP: 4.Comprehensive Insights on GALAXY Study in CIRCULATE-Japan
EP: 5.Is Clearance of ctDNA an Acceptable Surrogate End Point?
EP: 6.Recent Data from BESPOKE-CRC
EP: 7.DYNAMIC Clinical Trial: ctDNA Guiding Adjuvant Therapy in Stage II Colorectal Cancer
EP: 8.COBRA: Rates of ctDNA Clearance in Assay-Directed Therapy
EP: 9.Optimizing Clinical Research and Patient Perceptions of ctDNA Testing
EP: 10.Key Takeaways on the Clinical Utility of ctDNA in Colorectal Cancer
Recent Videos
Key Takeaways and Future Directions in Later Relapsed/Refractory MM
Key Takeaways/Final Comments
PERSEUS Trial: Adverse Events
PERSEUS Trial: Progression-Free Survival
CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies
Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
A Review of Outpatient Step-Up Dosing for Talquetamab in R/R MM
PERSEUS Trial: MRD Negativity
PERSEUS Trial: Design/Baseline Characteristics
The CHALLENGE Trial Helps Redefine Adjuvant Therapy With Exercise in CRC
Related Content
